Cancer patients monitored for years after experimental immune cell treatment
NCT ID NCT06701201
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 60 cancer patients who have already received SynKIR CAR T cell therapy to check for long-term side effects and see how well the treatment continues to work. Researchers will monitor for delayed reactions and measure survival over time. The goal is to understand the lasting safety and effectiveness of this personalized immune cell treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SynKIR CAR T cells (immune cells engineered to target cancer)
What this could lead to
If successful, this study could show that SynKIR CAR T cell therapy is safe and effective over the long term for certain cancers.
What could go wrong
This is a long-term follow-up study, not a new treatment trial. It only includes people who already received the therapy, so results may not apply to new patients. Risks include delayed side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Colorado Blood Cancer Institute, part of Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
-
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States